ACCESSWIRE
09 May 2022, 21:13 GMT+10
CAMBRIDGE, MA / ACCESSWIRE / May 9, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that that it will host its in-person Science and Technology Day for analysts and investors at 9:00 a.m. ET on Tuesday, May 17 in Boston, MA.
Moderna's Science and Technology Day will feature presentations from Stephen Hoge M.D., President, Melissa Moore Ph.D., Chief Scientific Officer, Scientific Affairs, and Moderna's mRNA and technical development platform scientists with a focus on the Company's newest advances from its commitment to basic and applied sciences.
A live webcast will be available under the 'Events and Presentations' in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for one year following the presentation.
About Moderna
In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA) to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.
Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.
Moderna Contact:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
Get a daily dose of Pennsylvania Sun news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Pennsylvania Sun.
More InformationGENEVA, Switzerland: The World Health Organization (WHO) has received a proposal by 13 member states requesting that Taiwan be allowed ...
BRUSSELS, Belgium: European Union foreign policy chief Josep Borrell has said that the bloc would ensure Ukraine that it has ...
Former U.S. President George W. Bush has made an embarrassing mistake in criticizing Russian President Vladimir Putin over his decision ...
WASHINGTON D.C.: The U.S. State Department has announced the launch of a new program to capture and analyze evidence of ...
JAKARTA, Indonesia: A new poll released this week indicated that Indonesian President Joko Widodo's approval rating has hit a six-year ...
EAST JAVA, Indonesia: A tourist bus crashed into a billboard on a highway on Indonesia's main island of Java this ...
KATHMANDU, Nepal - According to the World Organization for Animal Health (OIE), Nepal has reported its first cases of African ...
NEW YORK, New York - U.S. stock markets reversed sharp losses in late trading to eke out minor gains in ...
WASHINGTON D.C.: U.S. retail sales rose strongly in April, as consumers bought more motor vehicles and spent more at restaurants, ...
LONDON, England: The UK's jobless rate fell to a 48-year low in the first three months of 2022, it was ...
SYDNEY, NSW, Australia - A reduction of the official lending criteria in China has boosted stocks on the mainland, and ...
ISTANBUL, Turkey: As state lenders reduced the amount of dollar sales to prop up the currency for the ninth consecutive ...